AR062327A1 - Derivados de oxazolidona como moduladores de pr - Google Patents
Derivados de oxazolidona como moduladores de prInfo
- Publication number
- AR062327A1 AR062327A1 ARP070103552A ARP070103552A AR062327A1 AR 062327 A1 AR062327 A1 AR 062327A1 AR P070103552 A ARP070103552 A AR P070103552A AR P070103552 A ARP070103552 A AR P070103552A AR 062327 A1 AR062327 A1 AR 062327A1
- Authority
- AR
- Argentina
- Prior art keywords
- aryl
- alkyl
- perfluoroalkyl
- halogen
- independently
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/48—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/06—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing isoquinuclidine ring systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Diabetes (AREA)
- Gynecology & Obstetrics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Steroid Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Estos compuestos son de utilidad para tratar una variedad de condiciones patologicas relacionadas con hormonas que incluyen anticoncepcion, tratamiento o prevencion de fibroides, endometriosis, sangrado disfuncional, leiomiomas uterinos, síndrome ovárico poliquístico, o carcinomas dependientes de hormonas, que proveen terapia de reemplazo hormonal y que estimulan la ingesta de alimento o estro sincronizado. Reivindicacion 1: Un compuesto de la estructura (1) en donde R1, R2, R5 y R6 son, de modo independiente, H, alquilo C1-10, -(CH2)n-arilo, -(CH2)p-O-(CH2)n-arilo, -(CH2)nC(H)3-p(R7)p, -(CH2)nCOOR8, o -(CH2)p-O-Rg; o R1, R2 o R5, R6 se toman juntos para formar un anillo saturado carbonado de 3 a 6 miembros; o R1 o R2 forma un anillo saturado carbonado de 5 a 7 miembros con R5 o R6; o R1 o R2 forma un anillo aromático carbonado de 6 miembros con R5 o R6; R7 es halogeno; R8 es alquilo C1-6; R9 es H, alquilo C1-6, o perfluoroalquilo C1-3; V es O o S; X y Z son, de modo independiente, N o CR14; R14 es alquilo C1-6, -(CH2)n-arilo, -(CH2)n-O-(CH2)n-alquilo, -(CH2)n-O-(CH2)n-arilo, halogeno, hidroxi, perfluoroalquilo C1-3, perfluoroalcoxi C1-3, o -(CH2)n-CN; Y es O o S; Q es arilo, arilo sustituido, heteroarilo o heteroarilo sustituido; n es 0 a 3; p es 1 a 3; o una de sus sales, tautomeros, metabolitos o profármacos farmacéuticamente aceptables.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US83789806P | 2006-08-15 | 2006-08-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR062327A1 true AR062327A1 (es) | 2008-10-29 |
Family
ID=39082681
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP070103552A AR062327A1 (es) | 2006-08-15 | 2007-08-10 | Derivados de oxazolidona como moduladores de pr |
Country Status (22)
Country | Link |
---|---|
US (1) | US7618990B2 (es) |
EP (1) | EP2054410A2 (es) |
JP (1) | JP2010500409A (es) |
KR (1) | KR20090039774A (es) |
CN (1) | CN101501031B (es) |
AR (1) | AR062327A1 (es) |
AU (1) | AU2007284599B2 (es) |
BR (1) | BRPI0716622A2 (es) |
CA (1) | CA2659208A1 (es) |
CR (1) | CR10617A (es) |
GT (1) | GT200900032A (es) |
IL (1) | IL196886A0 (es) |
MX (1) | MX2009001698A (es) |
NO (1) | NO20090457L (es) |
NZ (1) | NZ574753A (es) |
PE (1) | PE20070753A1 (es) |
RU (1) | RU2009105113A (es) |
SA (1) | SA07280440B1 (es) |
SV (1) | SV2009003168A (es) |
TW (1) | TW200815428A (es) |
WO (1) | WO2008021331A2 (es) |
ZA (1) | ZA200901055B (es) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008112495A1 (en) * | 2007-03-09 | 2008-09-18 | Wyeth | Synthesis and characterization of polymorph form iii of 4-(2,(4,4-dimethyl-2-oxooxazolidin-3-yl)thiazol-4-yl)benzonitrile |
PE20081803A1 (es) * | 2007-03-09 | 2008-12-11 | Wyeth Corp | Sintesis y caracterizacion de la forma ii polimorfica de 4-(2-(4,4-dimetil-2-oxooxazolidin-3-il)tiazol-4-il)benzonitrilo |
CN101525310B (zh) * | 2009-04-21 | 2019-04-16 | 大连九信精细化工有限公司 | 1-苯甲酰基-3-(2-羟基-1,1-二甲基乙基)硫脲的合成方法 |
AU2011312490B2 (en) * | 2010-09-28 | 2015-06-25 | Radius Pharmaceuticals, Inc. | Selective androgen receptor modulators |
US9120818B2 (en) * | 2010-12-14 | 2015-09-01 | Merck Sharp & Dohme Corp. | Process and intermediates for preparing macrolactams |
JP6663866B2 (ja) * | 2014-07-03 | 2020-03-13 | セルジーン クオンティセル リサーチ,インク. | リジン特異的なデメチラーゼ−1の阻害剤 |
Family Cites Families (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1670338A1 (de) | 1966-03-14 | 1972-08-10 | Heyden Chem Fab | Verfahren zur Herstellung von antimikrobiell wirksamen Nitrofuranderivaten |
US3493565A (en) | 1966-03-14 | 1970-02-03 | Squibb & Sons Inc | 3-amino-5-(nitrofuryl)-1,2,4-oxadiazole derivatives |
NL6809997A (es) * | 1967-08-04 | 1969-02-06 | ||
GB1224995A (en) | 1968-09-20 | 1971-03-10 | Delalande Sa | New 5-propargyloxymethyl-2-substituted oxazolidinones and their process of preparation |
US4293558A (en) * | 1975-10-28 | 1981-10-06 | Eli Lilly And Company | Antiviral thiazolinyl benzimidazoles and derivatives |
CA1076582A (en) * | 1975-10-28 | 1980-04-29 | Charles J. Paget | Antiviral thiazolinyl or thiazinyl ketobenzimidazoles |
US4008243A (en) * | 1975-11-19 | 1977-02-15 | Eli Lilly And Company | Antiviral thiazolinyl or thiazinyl benzimidazole esters |
US4268679A (en) * | 1980-02-19 | 1981-05-19 | Ppg Industries, Inc. | 3-[5- or 3-Substituted-5- or 3-isoxazolyl]-1-allyl or alkyl-4-substituted-5-substituted or unsubstituted-2-imidazolidinones |
US4426527A (en) * | 1982-02-12 | 1984-01-17 | Ppg Industries, Inc. | 3-[5- Or 3-substituted-1,2,4-oxadiazol-3- or -5-yl]-1-substituted-4-substituted-5-substituted or unsubstituted-2-imidazolidinones |
DE3227329A1 (de) | 1982-07-22 | 1984-01-26 | Basf Ag, 6700 Ludwigshafen | Verfahren zur herstellung von 2-n,n-disubstituierten aminothiazolen |
US4756744A (en) * | 1985-06-24 | 1988-07-12 | Ppg Industries, Inc. | Herbicidally active 4-aminoalkylamino-3-isoxazolyl-2-imidazolidinone derivatives |
DE3723797A1 (de) | 1987-07-18 | 1989-01-26 | Merck Patent Gmbh | Oxazolidinone |
IE913855A1 (en) | 1990-11-06 | 1992-05-22 | Smithkline Beecham Corp | Imidazolidinone compounds |
DE69132944T2 (de) | 1990-11-30 | 2002-11-21 | Otsuka Pharmaceutical Co., Ltd. | Azolederivate als Inhibitor von Superoxide-Radikalen |
DE4335876A1 (de) * | 1993-10-17 | 1995-04-20 | Schering Ag | Kombination von Progesteronantagonisten und Antiöstrogenen mit partialer agonistischer Wirkung für die Hormonsubstitutions-Therapie für peri- und postmenopausale Frauen |
JPH07149745A (ja) | 1993-11-30 | 1995-06-13 | Hisamitsu Pharmaceut Co Inc | 新規な2−アミノチアゾール誘導体 |
WO1995015955A1 (de) | 1993-12-06 | 1995-06-15 | Basf Aktiengesellschaft | 2,4-diaminothiazole und ihre herstellung |
DE4425613A1 (de) | 1994-07-20 | 1996-01-25 | Bayer Ag | 5-gliedrige Heteroaryl-oxazolidinone |
DE19540027A1 (de) | 1995-10-27 | 1997-04-30 | Gruenenthal Gmbh | Substituierte Imidazolidin-2,4-dion-Verbindungen als pharmazeutische Wirkstoffe |
US5714607A (en) * | 1995-12-01 | 1998-02-03 | American Cyanamid Company | Process improvement in the synthesis of N- 3-(3-cyano-pyrazolo 1,5-a!pyrimidin-7-yl)phenyl!-N-ethylacetamide |
DE19601264A1 (de) * | 1996-01-16 | 1997-07-17 | Bayer Ag | Pyrido-annellierte Thienyl- und Furanyl-Oxazolidinone |
DE19649095A1 (de) | 1996-02-06 | 1997-08-07 | Bayer Ag | Neue Heteroaryl-Oxazolidinone |
DE19604223A1 (de) | 1996-02-06 | 1997-08-07 | Bayer Ag | Neue substituierte Oxazolidinone |
HRP970049A2 (en) | 1996-02-06 | 1998-04-30 | Bayer Ag | New heteroaryl oxazolidinones |
US6251897B1 (en) | 1996-07-31 | 2001-06-26 | Nikken Chemicals Co., Ltd | 6-phenyltetrahydro-1,3-oxazin-2-one derivative and pharmaceutical composition containing the same |
US5972372A (en) * | 1996-07-31 | 1999-10-26 | The Population Council, Inc. | Intravaginal rings with insertable drug-containing core |
US5819742A (en) * | 1996-11-06 | 1998-10-13 | Family Health International | Vaginal device for preventing conception or the transmission of sexually transmitted diseases, or both |
DE19732928C2 (de) | 1997-07-31 | 2000-05-18 | Gruenenthal Gmbh | Verwendung substituierter Imidazolidin-2,4-dion-Verbindungen als Schmerzmittel |
AU9648098A (en) * | 1997-10-27 | 1999-05-17 | Takeda Chemical Industries Ltd. | Adenosine a3 receptor antagonists |
US6562844B2 (en) * | 1998-01-23 | 2003-05-13 | Pharmacia & Upjohn Company | Oxazolidinone combinatorial libraries, compositions and methods of preparation |
BR9907183A (pt) * | 1998-01-23 | 2003-06-10 | Versicor Inc | Colet neas combinatórias de oxazolidinona, composições e processos de preparação |
AU3289299A (en) | 1998-02-19 | 1999-09-06 | Tularik Inc. | Antiviral agents |
JP2001261652A (ja) | 2000-03-21 | 2001-09-26 | Suntory Ltd | 二置換イミノヘテロサイクリック化合物 |
WO2001074811A2 (en) | 2000-03-30 | 2001-10-11 | Takeda Chemical Industries, Ltd. | Substituted 1,3-thiazole compounds, their production and use |
GB0009803D0 (en) * | 2000-04-25 | 2000-06-07 | Astrazeneca Ab | Chemical compounds |
DE10034622A1 (de) | 2000-07-17 | 2002-01-31 | Bayer Ag | Substituierte Imidazol-Derivate und deren Verwendung zur Herstellung von Arzneimitteln |
DE10034623A1 (de) | 2000-07-17 | 2002-01-31 | Bayer Ag | Heterocyclisch substituierte Pyridine als Cytokin-Inhibitoren |
DE10034628A1 (de) | 2000-07-17 | 2002-01-31 | Bayer Ag | Pyridinhaltige Oxazolidinone als Cytokin-Inhibitoren |
US20020115669A1 (en) * | 2000-08-31 | 2002-08-22 | Wiedeman Paul E. | Oxazolidinone chemotherapeutic agents |
FR2823209B1 (fr) | 2001-04-04 | 2003-12-12 | Fournier Lab Sa | Nouvelles thiohydantoines et leur utilisation en therapeutique |
GB0118407D0 (en) | 2001-07-27 | 2001-09-19 | Cipla Ltd | Oxazolidinone derivatives as antibacterial agents |
KR100437972B1 (ko) * | 2001-10-27 | 2004-07-02 | 한국과학기술연구원 | 피롤리디논 유도체, 이의 제조 방법 및 이를 포함하는제약 조성물 |
US7119111B2 (en) | 2002-05-29 | 2006-10-10 | Amgen, Inc. | 2-oxo-1,3,4-trihydroquinazolinyl derivatives and methods of use |
BR0313160A (pt) | 2002-08-08 | 2005-07-12 | Smithkline Beecham Corp | Composto, composição farmacêutica, métodos para tratar uma condição e um neoplasmo suscetìvel em um animal em um animal, processo para preparar um composto e uso de um composto |
TWI324596B (en) * | 2002-08-26 | 2010-05-11 | Nat Health Research Institutes | Imidazolamino compounds |
JP2006504679A (ja) | 2002-08-28 | 2006-02-09 | メルク フロスト カナダ アンド カンパニー | 緑内障の治療においてep4受容体作動薬として使用するためのオキサゾリジン−2−オンおよびチアゾリジン−2−オン誘導体 |
US20040167192A1 (en) * | 2003-01-16 | 2004-08-26 | David Solow-Cordero | Methods of treating conditions associated with an Edg-7 receptor |
US7169797B2 (en) * | 2003-02-14 | 2007-01-30 | Abbott Laboratories | Protein-tyrosine phosphatase inhibitors and uses thereof |
US20040235834A1 (en) | 2003-03-25 | 2004-11-25 | Farmer Luc J. | Thiazoles useful as inhibitors of protein kinases |
CN100387594C (zh) | 2003-04-03 | 2008-05-14 | 麦克公司 | 二芳基取代的吡唑类代谢型谷氨酸受体-5调节剂 |
CN1829721A (zh) | 2003-07-08 | 2006-09-06 | 阿斯利康(瑞典)有限公司 | 对α7烟碱乙酰胆碱受体具有亲和力的螺[1-氮杂二环[2.2.2]辛烷-3,5’-噁唑烷]-2’-酮衍生物 |
-
2007
- 2007-07-31 TW TW096127981A patent/TW200815428A/zh unknown
- 2007-08-10 AR ARP070103552A patent/AR062327A1/es not_active Application Discontinuation
- 2007-08-13 CA CA002659208A patent/CA2659208A1/en not_active Abandoned
- 2007-08-13 KR KR1020097002974A patent/KR20090039774A/ko not_active Application Discontinuation
- 2007-08-13 CN CN2007800302230A patent/CN101501031B/zh not_active Expired - Fee Related
- 2007-08-13 WO PCT/US2007/017931 patent/WO2008021331A2/en active Application Filing
- 2007-08-13 EP EP07836789A patent/EP2054410A2/en not_active Withdrawn
- 2007-08-13 NZ NZ574753A patent/NZ574753A/en not_active IP Right Cessation
- 2007-08-13 JP JP2009524654A patent/JP2010500409A/ja active Pending
- 2007-08-13 AU AU2007284599A patent/AU2007284599B2/en not_active Ceased
- 2007-08-13 RU RU2009105113/04A patent/RU2009105113A/ru not_active Application Discontinuation
- 2007-08-13 BR BRPI0716622-2A patent/BRPI0716622A2/pt not_active IP Right Cessation
- 2007-08-13 MX MX2009001698A patent/MX2009001698A/es active IP Right Grant
- 2007-08-13 US US11/891,748 patent/US7618990B2/en not_active Expired - Fee Related
- 2007-08-14 SA SA07280440A patent/SA07280440B1/ar unknown
- 2007-08-15 PE PE2007001100A patent/PE20070753A1/es not_active Application Discontinuation
-
2009
- 2009-01-29 NO NO20090457A patent/NO20090457L/no not_active Application Discontinuation
- 2009-02-03 IL IL196886A patent/IL196886A0/en unknown
- 2009-02-12 GT GT200900032A patent/GT200900032A/es unknown
- 2009-02-12 SV SV2009003168A patent/SV2009003168A/es unknown
- 2009-02-13 ZA ZA200901055A patent/ZA200901055B/xx unknown
- 2009-02-13 CR CR10617A patent/CR10617A/es unknown
Also Published As
Publication number | Publication date |
---|---|
US7618990B2 (en) | 2009-11-17 |
KR20090039774A (ko) | 2009-04-22 |
SA07280440B1 (ar) | 2010-10-20 |
PE20070753A1 (es) | 2008-08-14 |
IL196886A0 (en) | 2009-11-18 |
GT200900032A (es) | 2011-03-29 |
AU2007284599B2 (en) | 2011-07-21 |
RU2009105113A (ru) | 2010-09-27 |
NO20090457L (no) | 2009-04-27 |
AU2007284599A1 (en) | 2008-02-21 |
EP2054410A2 (en) | 2009-05-06 |
CN101501031B (zh) | 2012-02-01 |
WO2008021331A3 (en) | 2008-05-22 |
TW200815428A (en) | 2008-04-01 |
US20080045556A1 (en) | 2008-02-21 |
JP2010500409A (ja) | 2010-01-07 |
ZA200901055B (en) | 2009-12-30 |
CA2659208A1 (en) | 2008-02-21 |
WO2008021331A2 (en) | 2008-02-21 |
CR10617A (es) | 2009-03-12 |
CN101501031A (zh) | 2009-08-05 |
NZ574753A (en) | 2011-04-29 |
MX2009001698A (es) | 2009-02-25 |
SV2009003168A (es) | 2010-01-14 |
BRPI0716622A2 (pt) | 2013-10-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR062327A1 (es) | Derivados de oxazolidona como moduladores de pr | |
PE20070341A1 (es) | Derivados de pirrol como moduladores del receptor de progesterona | |
PE20141110A1 (es) | Derivados heterociclicos novedosos para el tratamiento de trastornos neurologicos | |
AR040333A1 (es) | Uso de derivados de ciclotiocarbamatos en el tratamiento de condiciones relacionadas con hormonas | |
AR078045A1 (es) | Derivados de pirimidina, composiciones farmaceuticas que los comprenden y su uso en la fabricacion de un medicamento para el tratamiento del cancer | |
UY25873A1 (es) | Derivados de 3-azabiciclo [3.1.0] hexano útiles en terapia en afecciones mediadas por receptores opiáceos | |
SE0201635D0 (sv) | Novel compounds | |
PE20110028A1 (es) | Derivados de isoxazol y su uso como potenciadores de los receptores metabotropicos de glutamato | |
EA200700047A1 (ru) | Новые алкильные производные в качестве метаботропных рецепторов глутамата | |
CY1108908T1 (el) | Ενωσεις κινολινονης - καρβοξαμιδης ως αγωνιστες υποδοχεων 5-ητ4 | |
ATE431345T1 (de) | Als modulatoren von dopamin-d3-rezeptoren geeignete azabicyclo-(3,1,0)-hexan-derivate | |
AR038882A1 (es) | Compuestos que modulan la actividad de ppar y composicion farmaceutica que los contiene | |
PE20060648A1 (es) | Procesos para la preparacion de 2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolinas sustituidas | |
PE20030809A1 (es) | Derivados de piperidina como antagonistas de la hormona concentradora de la melanina (mch) | |
TW200639158A (en) | New compounds with therapeutic effect | |
PE20060336A1 (es) | Compuestos derivados de 1-amino-ftalazina como moduladores de mch1 | |
PE20030062A1 (es) | Derivados aralquilsulfonil-3-(pirrol-2-ilmetiliden)-2-indolinona como inhibidores de quinasas | |
AR037907A1 (es) | Derivados de azaindolilalquilamina como ligandos de 5-hidroxitriptamina-6 | |
AR050274A1 (es) | Derivados triciclicos del indeno-pirrol como moduladores de la serotonina | |
PE20130401A1 (es) | Heteroaril-ciclohexil-tetraazabenzo[e]azulenos | |
PE20110793A1 (es) | Derivados de (3-(4-cianofenil)-1h-pirazol-5 carboxamida como antagonistas del receptor de progesterona | |
AR052175A1 (es) | Sulfonamido-macrociclos y sus sales, una composicion farmaceutica que comprende estos compuestos, un metodo de preparacion y el uso de los mismos | |
AR074817A1 (es) | Dihidropiridona-amidas como moduladores de p2x7 | |
CO6241119A2 (es) | Compuestos de pirido 2,3-d pirimidina-7-ona como inhibidores de pi3k-alfa para el tratamiento del cancer | |
AR068115A1 (es) | Derivado del acido pirazolcarboxilico metodo de produccion del mismo y fungicida |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |